Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Netflix Eyes South Korea for More Live Events as BTS Concert Livestream Approaches 
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures 
SLMG Beverages Eyes Price Hikes Amid Rising Packaging Costs and India's Booming Soft Drink Market 
Gold Prices Extend Losing Streak, On Track for Worst Weekly Loss Since 1983 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Qatar's Economy Under Pressure: How Regional Conflict Could Reshape Global Investment in 2026 
Volkswagen CEO Urges Germany to Adopt China's Industrial Discipline Amid Major Restructuring 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
Trump Signals End of U.S. Military Campaign Against Iran as Markets Rally 
Judge Dismisses Sam Altman Sexual Abuse Lawsuit, But Sister Can Refile 
Iran War Fears Send Oil Prices Surging as U.S. Weighs Ground Troop Deployment 
Iran-Israel War Escalates: Long-Range Missiles, Nuclear Site Strikes, and Global Energy Crisis 
Celltrion revealed on Thursday, Sept. 23, that it would be supplying its rapid COVID-19 test kit called DiaTrust to the US government. This happened after the nation’s Department of Defense awarded the contract to them.
The South Korean biopharma stated that starting October 1st, its American division, Celltrion USA, will begin delivering the DiaTrust rapid test kits to 25,000 locations. The sites include nursing homes, coronavirus testing centers, and military facilities.
According to The Korea Herald, based on the agreement signed by Celltrion and the US Defense Logistics Agency, the United States could purchase additional kits if necessary. For the initial supply, the amount of the contract is said to be $626.61 million or 738.2 billion in Korean won.
Details for the initial order, like how many would be delivered was not disclosed. However, the publication stated that Bloomberg mentioned that the deal was for a total of 19 million DiaTrust test kits. With its contract with the DOD, Celltrion became the US’ largest supplier of rapid COVID-19 test kits.
“The fact that we were awarded a procurement contract by the DLA after having passed its strict screen process is a recognition of Celltrion’s technology and supply capability,” Celltrion USA chief executive officer, Bonjoong Kim, said in a press release. “With the COVID-19 pandemic still not showing signs of waning, we plan to focus on executing this contract as diligently as possible and further solidify the external credibility of Celltrion’s diagnostic test kits portfolio.”
It was added that the DiaTrust kits that will be delivered through this deal are point-of-care tests (POCT). This means that the COVID-19 rapid test will only be used in the presence of medical professionals. Apparently, this is for safety and to ensure that the process is done properly for more accurate results.
As per Pulse News, DiaTrust was jointly developed by Celltrion and Humasis, a Korean R&D company. The test kit was authorized by the US Food and Drug Administration (FDA) for emergency use last April.
Finally, Celltrion’s DiaTrust rapid COVID-19 kit is an antigen test that is used in medical settings. It can reveal the results on the spot since it only takes as little as 15 minutes to complete.
